Welcome to Idorsia

We've made
outstanding
progress
in 2018 -
interested to
learn more?

Our key assets have
the potential to
transform treatment in
the target indications...

Read about how our IT department
achieved operational independence
ahead of schedule...

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

11 Sep 2019	Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis
03 Sep 2019	Phase 2 data of selatogrel, Idorsia’s highly-selective P2Y12 receptor antagonist, presented at ESC 2019
31 Aug 2019	Phase 2 data of aprocitentan, Idorsia’s dual endothelin receptor antagonist, presented at ESC 2019

Event	When
Nine-months 2019 Financial Results reporting*	October 22, 2019
Full-Year 2019 Financial Results reporting*	February 6, 2020
First Quarter 2020 Financial Results reporting*	April 23, 2020

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 17:31:18 CET

25.20 CHF

+0.08 (+0.32 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland